TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04089410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic Fitness Treatment (HFT)
Description: The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hyperthermic Fitness Treatment
Description: Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Examination
Description: Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand.
Study: NCT00332644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: dosage according to FDA-approved instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion + lozenge
Description: dosage according to FDA approved standard instructions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage same as active drug conditions
Study: NCT02823548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droglican
Description: Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01693419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GES (Gemcitabine, Erlotinib, S-1)
Description: Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14
Study: NCT02614560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously, 2 days before the transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Post-allo (after stem cell transplant) given on Day 1 of each cycle
Study: NCT03587363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
Study: NCT03182959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avmacol®
Description: Avmacol® tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avmacol®
Description: Avmacol® tablets
Study: NCT00419094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
Study: NCT04375449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep2dia
Description: what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep2dia
Description: what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin
Study: NCT02253719

Intervention type: PROCEDURE
Intervention: cryotherapy, further biopsy, LEEP, surgery as indicated
Description: These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.

Intervention type: PROCEDURE
Intervention: cryotherapy, further biopsy, LEEP, surgery as indicated
Description: These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
Study: NCT00839046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Intervention
Description: The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
Study: NCT00878657

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy
Study: NCT02813798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single 840mg dose of Rivipansel over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single 840mg dose of Rivipansel over 20 minutes
Study: NCT00839046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Filter
Description: Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Filter and Air Conditioner
Description: Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
Study: NCT03926559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine.
Description: Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
Study: NCT01700517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: spinal anesthesia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Spinal anesthesia
Description: spinal anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: spinal anesthesia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Femoral nerve block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Femoral nerve block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sciatic nerves block
Description: sciatic nerves block
Study: NCT02858609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Swab
Study: NCT01236612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization
Description: Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmodium falciparum Bloodstage challenge
Description: Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Bloodstage challenge
Description: Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmodium falciparum mosquito challenge
Description: Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study: NCT01466881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01236612

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum mosquito challenge
Description: Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT01466881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00391755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ramelteon
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary
Study: NCT01236612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT03219593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablets
Description: Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
Study: NCT00471445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine/amitriptyline NP-H cream
Description: Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study: NCT03629418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted blood-pressure management
Description: Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine blood-pressure management
Description: Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
Study: NCT05434247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle choice
Description: The type of needle use was the only intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle choice
Description: The type of needle use was the only intervention

Intervention type: DEVICE
Group type: OTHER
Intervention: Needle choice
Description: The type of needle use was the only intervention
Study: NCT02327286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promote and support healthy behaviors
Description: * Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices.
Study: NCT03645408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subject received an injection of 5 mcg of immediate release exenatide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subject received an injection of 5 mcg of immediate release exenatide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Subjects received a sham injection with no study drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Subjects received a sham injection with no study drug.
Study: NCT03126539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Narrow-band Ultraviolet B exposure
Description: The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 mm skin punch biopsy
Description: All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 mm skin punch biopsy
Description: All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
Study: NCT00308438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide (ALX-0600)
Description: 0.1 mg/kg injected subcutaneously daily
Study: NCT03121131

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Exam Findings
Description: Findings found on clinical exam of a patient the radiologist will be reading CT scans of.

Intervention type: OTHER
Group type: OTHER
Intervention: Inaccurate Clinical Exam Findings
Description: Inaccurate findings are given to the radiologists

Intervention type: OTHER
Group type: OTHER
Intervention: No clinical exam findings
Description: No clinical exam findings are given to the radiologists
Study: NCT04017169

Intervention type: OTHER
Intervention: No intervention as observational study
Study: NCT01028911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
Study: NCT04089410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of Cardiorespiratory Fitness
Description: An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
Study: NCT03178721

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: study B regulatory in blood and its correlation with atherosclerosis

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: study B regulatory in blood and its correlation with atherosclerosis
Study: NCT04939077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Description: In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
Study: NCT03239756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection
Study: NCT04293042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BK-virus specific CTLs
Description: HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg).
Study: NCT01577160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.